Published on 31 Jul 2023 on Simply Wall St. via Yahoo Finance

The past three years for Poseida Therapeutics (NASDAQ:PSTX) investors has not been profitable

It's not possible to invest over long periods without making some bad investments. But you want to avoid the really big losses like the plague. So consider, for a moment, the misfortune of Poseida Therapeutics, Inc. (NASDAQ:PSTX) investors who have held the stock for three years as it declined a whopping 87%. That would certainly shake our confidence in the decision to own the stock. And over the last year the share price fell 32%, so we doubt many shareholders are delighted. Furthermore, it's down 35% in about a quarter. That's not much fun for holders. We really hope anyone holding through that price crash has a diversified portfolio. Even when you lose money, you don't have to lose the lesson.

Since shareholders are down over the longer term, lets look at the underlying fundamentals over the that time and see if they've been consistent with returns.

View our latest analysis for Poseida Therapeutics